|
Variable
|
Evaluation
|
Hazard ratio (95% confidence interval)
|
P value
|
|---|
|
Tumour size
|
T1 (≤ 2 mm)
|
1
| |
| |
T2 (2 < T ≤ 5 mm)
|
1.57 (0.70 to 3.51)
|
0.265
|
| |
T3 (>5 mm)
|
3.12 (1.16 to 8.41)
|
0.024
|
|
Lymph node stage
|
Negative
|
1
| |
| |
1 to 3 lymph nodes
|
0.56 (0.20 to 1.56)
|
0.272
|
| |
>3 lymph nodes
|
2.68 (1.30 to 5.49)
|
0.007
|
|
Tumour grade
|
Grade I
|
1
| |
| |
Grade II
|
2.60 (0.58 to 11.56)
|
0.208
|
| |
Grade III
|
7.65 (1.80 to 32.48)
|
0.006
|
|
ER expression
|
ER-positive
|
1
| |
| |
ER-negative
|
2.94 (1.52 to 5.57)
|
0.001
|
|
PR expression
|
PR-positive
|
1
| |
| |
PR-negative
|
2.16 (1.04 to 4.46)
|
0.038
|
|
HER-2/neu expression
|
HER-2/neu-negative
|
1
| |
| |
HER-2/neu-positive
|
2.47 (1.19 to 5.09)
|
0.014
|
|
FOXA1 expression
|
FOXA1-positive
|
1
| |
| |
FOXA1-negative
|
4.25 (1.76 to 10.28)
|
0.001
|
|
GATA-3 expression
|
GATA-3-positive
|
1
| |
| |
GATA-3-negative
|
1.97 (0.96 to 4.01)
|
0.061
|
- ER, oestrogen receptor; FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human epidermal growth factor receptor 2; PR, progesterone receptor.
